← Back to Search

Plasma Gelsolin

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

Saint Paul, MN
Phase 1
Waitlist Available
Research Sponsored by BioAegis Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 108 hours

Summary

This trial tests the safety of a new protein treatment in healthy adults. The goal is to see how this protein behaves in the body and ensure it is safe for future use.

See full description
Eligible Conditions
  • Volunteers
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~108 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 108 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events
Serious Adverse Events
Secondary study objectives
Pharmacokinetics: pGSN Area Under the Curve (AUC)
Pharmacokinetics: pGSN Concentration
Pharmacokinetics: pGSN Half-life
+1 more

Side effects data

From 2023 Phase 1 trial • 32 Patients • NCT05789745
17%
Epigastric discomfort
17%
Dermatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort 4 (24 mg/kg)
Cohort 1 (6 mg/kg)
Cohort 2 (12 mg/kg)
Cohort 3 (18 mg/kg)
Placebo Cohorts 1-4

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: rhu-pGSNExperimental Treatment1 Intervention
Treated with 5 doses of rhu-pGSN
Group II: normal salinePlacebo Group1 Intervention
Treated with 5 doses of saline
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Recombinant human plasma gelsolin
2023
Completed Phase 1
~40

Find a Location

Closest Location:Nucleus Network· Saint Paul, MN

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

BioAegis Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
733 Total Patients Enrolled
Mark J DiNubile, MDStudy DirectorBioAegis Therapeutics
2 Previous Clinical Trials
97 Total Patients Enrolled
~11 spots leftby Feb 2026